Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as TOBRADEX Ophthalmic Suspension
TOBRADEX · 1 trial · 1 indication
Tear samples were collected to measure tobramycin concentrations at 2, 4, 6, 12, and 18 minutes post-drop instillation in each subject's right eye for each treatment period.
| Arm | Type | Description |
|---|---|---|
| Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension | EXPERIMENTAL | Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension |
| TOBREX® Ophthalmic Solution | ACTIVE_COMPARATOR | TOBREX® Ophthalmic Solution |
| TOBRADEX® Ophthalmic Suspension | ACTIVE_COMPARATOR | TOBRADEX® Ophthalmic Suspension |
| Name | Type | Description |
|---|---|---|
| TOBRADEX Ophthalmic Suspension | DRUG | TOBRADEX Ophthalmic Suspension 1 drop each eye at baseline |
| Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension | DRUG | Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension 1 drop each eye at baseline |
| TOBREX Ophthalmic Solution | DRUG | TOBREX Ophthalmic Solution 1 drop each eye at baseline |
Inclusion: * Visual Acuity (VA) of 0.6 logMAR or better * Tear meniscus height of ≥ 0.3mm at Visit 1. * No concomitant topical ocular medications, including artificial tears, during the study period Exclusion * ocular hypertension, iritis or uveitis, glaucoma * ocular surgery, intraocular surgery...
TOBRADEX is an ophthalmic suspension developed by Alcon Inc. (ticker ALC). It is being studied in a Phase 1 clinical program for dry eye, an ophthalmology condition. The formulation is a small molecule product, and it is also referred to as TOBRADEX Ophthalmic Suspension.
TOBRADEX is being evaluated for dry eye. Its clinical development in this indication is at the Phase 1 stage, and the program includes one completed trial conducted in the United States. The drug is investigational for dry eye and is not described as approved for that use.
TOBRADEX is developed by Alcon Inc., which trades under the ticker ALC. Alcon is the sponsor behind the clinical program evaluating the ophthalmic suspension in dry eye.
TOBRADEX is in Phase 1 development for dry eye. The program has one completed Phase 1 trial and no active trials. Because the available development stage is Phase 1, TOBRADEX is investigational and remains in clinical development rather than being an approved therapy.
TOBRADEX has been studied in one completed Phase 1 trial, NCT00695435, titled Tobramycin Tear Concentrations. That trial enrolled 21 participants in the United States, used a randomized, double-blind, active-controlled design, and included healthy volunteers aged 18 years and older.
Yes. TOBRADEX Ophthalmic Suspension is another name for TOBRADEX. Both names refer to the same Alcon Inc. product, a small molecule ophthalmic suspension being studied in Phase 1 for dry eye.